CA2395324A1 - Expression potentiator for protein synthesis regulatory gene - Google Patents

Expression potentiator for protein synthesis regulatory gene Download PDF

Info

Publication number
CA2395324A1
CA2395324A1 CA002395324A CA2395324A CA2395324A1 CA 2395324 A1 CA2395324 A1 CA 2395324A1 CA 002395324 A CA002395324 A CA 002395324A CA 2395324 A CA2395324 A CA 2395324A CA 2395324 A1 CA2395324 A1 CA 2395324A1
Authority
CA
Canada
Prior art keywords
ifn
alpha
subtypes
expression
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002395324A
Other languages
English (en)
French (fr)
Inventor
Yoshiaki Yanai
Osamu Sano
Masashi Kurimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2395324A1 publication Critical patent/CA2395324A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
CA002395324A 2000-10-27 2001-09-26 Expression potentiator for protein synthesis regulatory gene Abandoned CA2395324A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000-328539 2000-10-27
JP2000328539 2000-10-27
JP2001116710A JP2002201141A (ja) 2000-10-27 2001-04-16 蛋白質合成抑制遺伝子の発現増強剤
JP2001-116710 2001-04-16
PCT/JP2001/008390 WO2002036153A1 (en) 2000-10-27 2001-09-26 Expression potentiator for protein synthesis regulatory gene

Publications (1)

Publication Number Publication Date
CA2395324A1 true CA2395324A1 (en) 2002-05-10

Family

ID=26602905

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002395324A Abandoned CA2395324A1 (en) 2000-10-27 2001-09-26 Expression potentiator for protein synthesis regulatory gene

Country Status (7)

Country Link
US (2) US6773701B2 (cg-RX-API-DMAC7.html)
EP (1) EP1329223A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002201141A (cg-RX-API-DMAC7.html)
KR (1) KR100830268B1 (cg-RX-API-DMAC7.html)
CA (1) CA2395324A1 (cg-RX-API-DMAC7.html)
TW (1) TWI283582B (cg-RX-API-DMAC7.html)
WO (1) WO2002036153A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP4629964B2 (ja) * 2003-09-12 2011-02-09 株式会社林原生物化学研究所 ウシの消化器疾患治療剤
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
EP1867340A4 (en) 2005-03-10 2009-12-23 Hayashibara Biochem Lab THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM
JPWO2007037098A1 (ja) * 2005-09-27 2009-04-02 株式会社林原生物化学研究所 繁殖障害改善剤
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
CN104056254A (zh) * 2013-03-18 2014-09-24 赛德医药科技股份有限公司 用以降低肝炎病患复发率的组合物
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5142199B2 (cg-RX-API-DMAC7.html) 1972-09-04 1976-11-13
GB2016015B (en) 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
JPS5639022A (en) 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS5654158A (en) 1979-10-09 1981-05-14 Hitachi Ltd Control system for call waiting
JP2838800B2 (ja) 1989-09-02 1998-12-16 株式会社林原生物化学研究所 減感作剤
US5503828A (en) * 1992-02-10 1996-04-02 Interferon Sciences, Inc. Alpha interferon composition and method for its production from human peripheral blood leukocytes
JP3232488B2 (ja) 1992-08-20 2001-11-26 株式会社林原生物化学研究所 プルラン高含有物とその製造方法並びに用途
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
JPH07163368A (ja) 1993-12-15 1995-06-27 Hayashibara Biochem Lab Inc 組換えdnaとその組換えdnaを含む形質転換体
EP0785276A4 (en) 1994-09-29 2002-01-09 Ajinomoto Kk MODIFICATION OF A PEPTIDE AND A PROTEIN
JP3467515B2 (ja) * 1994-11-01 2003-11-17 財団法人ルイ・パストゥール医学研究センター インターフェロン活性の測定法
MY125300A (en) * 1999-02-26 2006-07-31 Inst Of Molecular And Cell Biology Synergistic combination for treatment of viral-mediated diseases

Also Published As

Publication number Publication date
EP1329223A1 (en) 2003-07-23
KR100830268B1 (ko) 2008-05-16
US6773701B2 (en) 2004-08-10
US20040197307A1 (en) 2004-10-07
US7189389B2 (en) 2007-03-13
KR20020065620A (ko) 2002-08-13
EP1329223A4 (en) 2005-04-20
JP2002201141A (ja) 2002-07-16
US20030039629A1 (en) 2003-02-27
TWI283582B (en) 2007-07-11
WO2002036153A1 (en) 2002-05-10

Similar Documents

Publication Publication Date Title
KR100223255B1 (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로 부터의 제조 방법
Grace et al. Structural and biologic characterization of pegylated recombinant IFN-α 2b
US5981709A (en) α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
ES2436761T3 (es) Mutantes de interferón alfa 2 (IFN alfa 2) recombinante
Lefevre et al. A novel and atypical type one interferon gene expressed by trophoblast during early pregnancy.
KR100496460B1 (ko) 폴리펩티드
Schultz et al. Recombinant chicken interferon from Escherichia coli and transfected COS cells is biologically active
JPWO1990010651A1 (ja) ヒト由来の糖蛋白質及び該糖蛋白質からなる生理活性因子とそれを活性成分とする製剤
US6773701B2 (en) Expression enhancer for protein synthesis inhibitory genes
CN103483443A (zh) 重组人干扰素样蛋白
Masci et al. New and modified interferon alfas: preclinical and clinical data
EP1326628B1 (en) Chemokine mutants in the treatment of multiple sclerosis
JP3226918B2 (ja) 腫瘍壊死因子とインターロイキン−4の相乗作用
JPH0550273B2 (cg-RX-API-DMAC7.html)
US6207641B1 (en) Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
CZ20024094A3 (cs) Farmaceutický přípravek pro léčení sclerosis multiplex obsahující nový interferon
Franco et al. Biological activities of a human amniotic membrane interferon
KR100891918B1 (ko) Ifnar2 돌연변이, 및 그 제조방법 및 용도
RU2003334C1 (ru) Способ лечени больных с опухол ми
US6774220B1 (en) Compounds having lectinic properties and their biological applications
Hayes Differences between human α (leukocyte) and β (fibroblast) interferons
Cheng et al. Accumulation of Guanylate Binding Proteins in Patients Treated with Interfeons
Horisberger et al. Induction of Mx-related protein in cat peripheral blood mononuclear cells after administration of recombinant human interferon hybrid
Finter The classification and biological functions of the interferons: A review
KR20080037656A (ko) 저독성의 장시간 순환하는 사람 인터페론-알파 유사체 및인터페론 타우의 키메라

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued